Hypersialylation is a common feature of neurofibrillary tangles and granulovacuolar degenerations in Alzheimer's disease and tauopathy brains

Neuropathology

Volumn 36, Issue 4, 2016, Pages 333-345

  Nagamine, Shun ^a   Yamazaki, Tsuneo ^b   Makioka, Kouki ^a   Fujita, Yukio ^a   Ikeda, Masaki ^a   Takatama, Masamitsu ^a   Okamoto, Koichi ^a   Yokoo, Hideaki ^a   Ikeda, Yoshio ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b GUNMA UNIVERSITY   (Japan)

Author keywords

Alzheimer's disease; granulovacuolar degeneration; hypersialylation; neurofibrillary tangle; tauopathy

Indexed keywords

MELANIN; SIALIC ACID; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; FEMALE; FRONTOTEMPORAL DEMENTIA; GRANULOVACUOLAR DEGENERATION; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; HYPERSIALYLATION; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LEWY BODY; MALE; MIDDLE AGED; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; PATHOGENESIS; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN PHOSPHORYLATION; SENILE PLAQUE; SIALYLATION; TAUOPATHY;

EID: 84978699373     PISSN: 09196544     EISSN: 14401789     Source Type: Journal    
DOI: 10.1111/neup.12277     Document Type: Article

References (48)

1. Lee VM, Balin BJ, Otvos L Jr., Trojanowski JQ. A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. Science 1991; 251: 675–78.
2. Alonso AD, Zaidi T, Novak M, Barra HS, Grundke-Iqbal I, Iqbal K. Interaction of tau isoforms with Alzheimer's disease abnormally hyperphosphorylated tau and in vitro phosphorylation into the disease-like protein. J Biol Chem 2001; 276: 37967–73.
3. Wang JZ, Grundke-Iqbal I, Iqbal K. Glycosylation of microtubule-associated protein tau: an abnormal posttranslational modification in Alzheimer's disease. Nat Med 1996; 2: 871–75.
4. Liu F, Zaidi T, Iqbal K, Grundke-Iqbal I, Merkle RK, Gong CX. Role of glycosylation in hyperphosphorylation of tau in Alzheimer's disease. FEBS Lett 2002; 512: 101–06.
5. Gong CX, Liu F, Grundke-Iqbal I, Iqbal K. Post-translational modifications of tau protein in Alzheimer's disease. J Neural Transm 2005; 112: 813–38.
6. Liu F, Iqbal K, Grundke-Iqbal I, Gong CX. Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta. FEBS Lett 2002; 530: 209–14.
7. Maguire TM, Gillian AM, O'Mahony D, Coughlan CM, Dennihan A, Breen KC. A decrease in serum sialyltransferase levels in Alzheimer's disease. Neurobiol Aging 1994; 15: 99–102.
8. Maguire TM, Breen KC. A decrease in neural sialyltransferase activity in Alzheimer's disease. Dementia (Basel, Switzerland) 1995; 6: 185–90.
9. Fodero LR, Sáez-Valero J, Barquero MS, Marcos A, McLean CA, Small DH. Wheat germ agglutinin-binding glycoproteins are decreased in Alzheimer's disease cerebrospinal fluid. J Neurochem 2001; 79: 1022–26.
10. Davis G, Baboolal N, Nayak S, McRae A. Sialic acid, homocysteine and CRP: potential markers for dementia. Neurosci Lett 2009; 465: 282–84.
11. Kitazume S, Nakagawa K, Oka R et al. In vivo cleavage of alpha2,6-sialyltransferase by Alzheimer beta-secretase. J Biol Chem 2005; 280: 8589–95.
12. Rosenthal SL, Kamboh MI. Late-Onset Alzheimer's Disease Genes and the Potentially Implicated Pathways. Curr Genet Med Rep 2014; 2: 85–101.
13. Hollingworth P, Harold D, Sims R et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet 2011; 43: 429–35.
14. Thal DR, Del Tredici K, Ludolph AC et al. Stages of granulovacuolar degeneration: their relation to Alzheimer's disease and chronic stress response. Acta Neuropathol 2011; 122: 577–89.
15. Dickson DW, Ksiezak-Reding H, Davies P, Yen SH. A monoclonal antibody that recognizes a phosphorylated epitope in Alzheimer neurofibrillary tangles, neurofilaments and tau proteins immunostains granulovacuolar degeneration. Acta Neuropathol 1987; 73: 254–58.
16. Morris JC, Heyman A, Mohs RC et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 1989; 39: 1159–65.
17. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239–59.
18. Mirra SS, Heyman A, McKeel D et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991; 41: 479–86.
19. Hyman BT, Phelps CH, Beach TG et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 2012; 8: 1–13.
20. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181–84.
21. Gelb DJ, Oliver E, Gilman S, Gelb DJ, Oliver E, Gilman S. Diagnostic Criteria for Parkinson Disease. Arch Neurol 1999; 56: 33.
22. Gilman S, Wenning GK, Low PA et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008; 71: 670–76.
23. Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron D. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1: 293–99.
24. Hauw JJ, Daniel SE, Dickson D et al. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 1994; 44: 2015–19.
25. Cairns NJ, Bigio EH, Mackenzie IR et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol 2007; 114: 5–22.
26. Lindenberg R, Rubinstein LJ, Herman MM, Haydon GB. A light and electron microscopy study of an unusual widespread nuclear inclusion body disease. A possible residuum of an old herpesvirus infection. Acta Neuropathol 1968; 10: 54–73.
27. Takahashi-Fujigasaki J. Neuronal intranuclear hyaline inclusion disease. Neuropathology 2003; 23: 351–59.
28. Fujita Y, Ohama E, Takatama M, Al-Sarraj S, Okamoto K. Fragmentation of Golgi apparatus of nigral neurons with alpha-synuclein-positive inclusions in patients with Parkinson's disease. Acta Neuropathol 2006; 112: 261–65.
29. Wakabayashi K, Hayashi S, Yoshimoto M, Kudo H, Takahashi H. NACP/alpha-synuclein-positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson's disease brains. Acta Neuropathol 2000; 99: 14–20.
30. Kadokura A, Yamazaki T, Kakuda S et al. Phosphorylation-dependent TDP-43 antibody detects intraneuronal dot-like structures showing morphological characters of granulovacuolar degeneration. Neurosci Lett 2009; 463: 87–92.
31. Hidari KI, Yamaguchi M, Ueno F, Abe T, Yoshida K, Suzuki T. Influenza virus utilizes N-linked sialoglycans as receptors in A549 cells. Biochem Biophys Res Commun 2013; 436: 394–99.
32. Ozawa H, Kotani M, Kawashima I, Tai T. Generation of one set of monoclonal antibodies specific for b-pathway ganglio-series gangliosides. Biochim Biophys Acta 1992; 1123: 184–90.
33. Lowe JMS, Hyman BT, Dickson DW. Ageing and dementia. In: Love S, Louis DN, Ellison DW, eds. Greenfield's Neuropathology, vol. 1, 8th edn. London: Edward Arnold Publishers, 2008; 1031–152.
34. Hoozemans JJ, van Haastert ES, Nijholt DA, Rozemuller AJ, Eikelenboom P, Scheper W. The unfolded protein response is activated in pretangle neurons in Alzheimer's disease hippocampus. Am J Pathol 2009; 174: 1241–51.
35. Dunn WA Jr. Studies on the mechanisms of autophagy: maturation of the autophagic vacuole. J Cell Biol 1990; 110: 1935–45.
36. Eskelinen EL, Eskelinen E-L. Roles of LAMP-1 and LAMP-2 in lysosome biogenesis and autophagy. Mol Aspects Med 2006; 27: 495.
37. Murayama S, Mori H, Ihara Y, Tomonaga M. Immunocytochemical and ultrastructural studies of Pick's disease. Ann Neurol 1990; 27: 394–405.
38. Schwab C, DeMaggio AJ, Ghoshal N, Binder LI, Kuret J, McGeer PL. Casein kinase 1 delta is associated with pathological accumulation of tau in several neurodegenerative diseases. Neurobiol Aging 2000; 21: 503–10.
39. Schneider A, Mandelkow E. Tau-based treatment strategies in neurodegenerative diseases. Neurotherapeutics 2008; 5: 443–57.
40. Lagalwar S, Berry RW, Binder LI. Relation of hippocampal phospho-SAPK/JNK granules in Alzheimer's disease and tauopathies to granulovacuolar degeneration bodies. Acta Neuropathol 2007; 113: 63–73.
41. Arima K, Hirai S, Sunohara N et al. Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein-epitopes in lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies. Brain Res 1999; 843: 53–61.
42. Ishizawa T, Mattila P, Davies P, Wang D, Dickson DW. Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. J Neuropathol Exp Neurol 2003; 62: 389–97.
43. Hoozemans JJ, van Haastert ES, Eikelenboom P, de Vos RA, Rozemuller JM, Scheper W. Activation of the unfolded protein response in Parkinson's disease. Biochem Biophys Res Commun 2007; 354: 707–11.
44. Makioka K, Yamazaki T, Fujita Y, Takatama M, Nakazato Y, Okamoto K. Involvement of endoplasmic reticulum stress defined by activated unfolded protein response in multiple system atrophy. J Neurol Sci 2010; 297: 60–65.
45. Ruddock LW, Molinari M. N-glycan processing in ER quality control. J Cell Sci 2006; 119: 4373–80.
46. Xi H, Kurtoglu M, Liu H et al. 2-Deoxy-D-glucose activates autophagy via endoplasmic reticulum stress rather than ATP depletion. Cancer Chemother Pharmacol 2011; 67: 899–910.
47. Guevara J, Espinosa B, Zenteno E et al. Altered glycosylation pattern of proteins in Alzheimer disease. J Neuropathol Exp Neurol 1998; 57: 905–14.
48. Joachim CL, Morris JH, Selkoe DJ, Kosik KS. Tau epitopes are incorporated into a range of lesions in Alzheimer's disease. J Neuropathol Exp Neurol 1987; 46: 611–22.